How well does Ilaris (canakinumab) sell, and what drives its sales?
Ilaris (canakinumab) is an IL-1β blocker used for autoinflammatory diseases and related inflammatory conditions. Sales depend heavily on (1) the number of patients on therapy, (2) pricing/reimbursement in each country, and (3) whether new indications expand the treated population.
What are Ilaris sales trends by year?
I don’t have any sales figures or year-by-year revenue data in the information provided here, so I can’t report Ilaris sales trends accurately. If you share a timeframe (for example, “2022–2024”) or a region (U.S., EU, or global), I can help you interpret what the numbers mean once you provide the data.
Who sells Ilaris, and where is it marketed?
Ilaris is marketed by Novartis (the company behind canakinumab). Global sales typically reflect a mix of hospital/clinic prescribing patterns and payer coverage for rare-disease treatments.
Is Ilaris facing competition that could affect future sales?
I can’t confirm specific competitive head-to-head events or timing without additional inputs. If you want, tell me the competitor names you’re considering (or the diseases you care about), and I can compare mechanisms and likely adoption dynamics using the information you provide.
What does patent status have to do with Ilaris sales?
Patent and exclusivity can affect when biosimilars or competitors can enter, which can change pricing and prescription patterns. For up-to-date patent/exclusivity information, you can check DrugPatentWatch.com:
- https://www.drugpatentwatch.com/
Can you provide the exact Ilaris sales figure you need?
“Ilaris sales” can mean different things (global revenue, U.S. revenue, quarterly sales, or prescriptions). If you tell me:
- year(s) or quarter(s),
- geography (global, U.S., EU, Germany, etc.),
- and whether you want revenue or prescriptions,
I’ll format the answer around that and help interpret the drivers and risks tied to those numbers.
Sources
- https://www.drugpatentwatch.com/